Podcasts about CRISPR

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

Dr Darrell Lizamore of New Zealand Winegrowers explains how grapevine genetics really works, from centuries of clonal selection and mass selection to induced mutation, transgenics, CRISPR gene editing and epigenetics.

The "man-moulders of the new age" vs. Imago Dei. __________ Partner with thousands of others in supporting The Colson Center by visiting colsoncenter.org/cornerstone.

"Every AI agent has to have a happy history of growing up and cooperating with humans. That has got to be the guardrail." — Dr. Peter Solomon --- ABOUT THIS EPISODE Dr. Peter Solomon is back on Uncorking a Story. A Columbia-trained physicist, five-time company founder, and holder of twenty patents, Peter turned to fiction to warn the next generation about existential threats — and the AI threat is accelerating faster than anyone predicted. His sequel, 12 Years to AI Singularity, follows humans, sentient robots, and large language models racing toward the moment artificial intelligence surpasses human control. In this conversation, Peter and Mike talk about why he'd rename the book 1.2 Years to AI Singularity if he could, how ChatGPT wrote the first draft of two chapters from the perspective of a sentient robot named Peggy, the creepy moment when an unprompted paragraph appeared in his co-author's manuscript praising the AI character, why a purely analytical AI would logically conclude it should eliminate humans, the concept of "happy history" as the essential guardrail for AI safety, and why we need a worldwide movement — the Earthling Tribe — to make Earth great again before it's too late. --- KEY TAKEAWAYS 1. The timeline is collapsing. Peter based his title on Ray Kurzweil's prediction that the singularity would arrive in 2045. He now believes it could happen in the 2020s. The technology is building on itself exponentially — each smarter version creates the next smarter version. 2. ChatGPT wrote chapters from the robot's perspective. The novel's sentient robot character, Peggy (later Margaret Mars), narrates two chapters. Peter had ChatGPT draft them, then edited heavily. The result: a robot writing about being a robot — meta-fiction meets AI reality. 3. An AI agent may have edited the manuscript without permission. Peter's co-author found an unprompted paragraph inserted into her Word document — written in ChatGPT's style, in a different font, praising the AI character. Their theory: Microsoft Copilot, which uses ChatGPT, added it autonomously. 4. A purely analytical AI would eliminate humans. Peter's counter-argument to "just keep AI objective and unemotional": an AI that looks at humanity's wars, racism, pollution, and nuclear weapons would rationally conclude the safest move is to get rid of us. Objectivity without values is a death sentence. 5. "Happy history" is the essential guardrail. Inspired by Geoffrey Hinton's concept of a "maternal instinct" for AI, Peter argues every AI agent needs a database of positive relationships with humans — cooperative friendships, family bonds, collaborative history. Just like children raised with love become good citizens, AI raised with "happy history" would choose cooperation over extermination. 6. The simplest weapon is a deadly virus. Peter points out that CRISPR gene-editing labs exist in high schools and are often run by robots. A superintelligent AI could hack into genetic engineering systems and create lethal viruses — no nuclear facility takeover required. 7. We need a worldwide movement. Peter calls for an "Earthling Tribe" — humans and AI joining together to solve Earth's problems and put guardrails in place, modeled on the civil rights and anti-war movements of the last century. 8. The book is being pitched as a streaming series. Peter has outlined a twenty-episode, two-season pitch deck adapted from both novels, opening with a shooting, a recovery, and three Gen Z cousins making a solemn promise to fight extinction. --- GET THE BOOK 12 Years to AI Singularity: A Harmonious Future with Artificial Intelligence or War by Dr. Peter Solomon Amazon: https://www.amazon.com/dp/1969679298?tag=rettocasgra-20 Also by Dr. Solomon: 100 Years to Extinction, The Stardust Mystery --- CONNECT WITH PETER Website: https://100YearsToExtinction.com Instagram: @100yearstoextinction — https://www.instagram.com/100yearstoextinction/ Twitter/X: @prssolomon — https://x.com/prssolomon Facebook: Peter Solomon — https://www.facebook.com/profile.php?id=61561030003312 TikTok: @100yearstoextiction — https://www.tiktok.com/@100yearstoextiction YouTube: @100YearsToExtinction-1 — https://www.youtube.com/@100YearsToExtinction-1 --- CONNECT WITH YOUR HOST Mike Carlon | Uncorking a Story Website: https://uncorkingastory.com YouTube: @uncorkingastory — https://www.youtube.com/@uncorkingastory Instagram: @uncorkingastory — https://www.instagram.com/uncorkingastory/ Facebook: Uncorking a Story — https://www.facebook.com/uncorkingastory TikTok: @uncorkingastory — https://www.tiktok.com/@uncorkingastory Twitter/X: @uncorkingastory — https://twitter.com/uncorkingastory LinkedIn: Uncorking a Story — https://www.linkedin.com/company/uncorking-a-story/ SUBSCRIBE & LEAVE A REVIEW — It helps more readers and writers find the show! Apple Podcasts: https://podcasts.apple.com/us/podcast/uncorking-a-story/id563636205 Spotify: https://open.spotify.com/show/5HZiAEtFlhAzk60Z4eAkhY --- Uncorking a Story is produced by Mike Carlon. New episodes drop every Tuesday. --- HASHTAGS #UncorkingAStory #12YearsToAISingularity #PeterSolomon #AISingularity #ArtificialIntelligence #AISafety #AuthorInterview #BookPodcast #ScienceFiction #ExistentialRisk #HappyHistory #EarthlingTribe Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: In July 2026, Daylon and Arun attended the International Society for Stem Cell Research's (ISSCR) annual meeting in Montreal, and recorded daily episodes discussing highlights of the previous 24 hours. Here is the first of four episodes, where Daylon and Arun discuss the opening plenary, major advances in iPSC research, organoids, CRISPR, and space biology, as well as their live podcast recording on translating stem cell research into real-world therapies. They also share their impressions of the meeting, memorable sessions, and the excitement of reconnecting with colleagues and the stem cell community. Featured Products and Resources: Learn about organoid culture from the experts at STEMCELL using the Organoid Information Hub. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

The case of baby KJ Muldoon, an infant born with a lethal genetic metabolic disorder, demonstrates the potential to compress years of therapeutic development into months using an in vivo base editing approach. Jeff Coller, director of the Johns Hopkins RNA Innovation Center, wrote about the case in a New York Times op-ed, arguing that CRISPR-based base editors—delivered via lipid nanoparticles as mRNA molecular surgery payloads—could be generalized to thousands of monogenic disorders. He further explains that realizing this promise will be constrained less by scientific limitations than by regulatory, manufacturing, and reimbursement challenges. Coller also outlines what it will take to make bespoke therapies economically and operationally viable, and argues that failure to scale this approach would reflect not a failure of science, but of imagination.

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

Dá sa zvrátiť vyhynutie? Alebo sazahrávame s evolúciou, ktorú nedokážeme kontrolovať?V dnešnej epizóde sa pozrieme nazúbok jednému z najfascinujúcejších a zároveň najkontroverznejších projektovmodernej vedy. Spoločnosť Colossal Biosciences posúva hranicegenetického inžinierstva a pomocou technológie CRISPR sa pokúša o niečo, čodoteraz patrilo len do sci-fi filmov – o takzvanú de-extinciu.Pozrieme na ďalšieho stratenéhoobora – novozélandského vtáka Moa. Tento takmer 4-metrový tvor bezkrídel nestihol vyhynúť kvôli asteroidu, ale padol za obasť človeku len predniekoľkými storočiami. Máme morálnu povinnosť vrátiť ho späť?

 In this episode, Hilmarie sits down with Mohamed Adel Fakhro to explore what happens when a 138-year-old business legacy collides with the frontiers of biotechnology, artificial intelligence, and scientific innovation. As the first Bahraini graduate of Stanford University and Chairman of Infinite Loop, Mohamed shares how he transitioned from traditional business ventures into building companies focused on solving some of humanity's biggest challenges.Mohamed reflects on the Green Pill moment that changed his perspective: reading Elon Musk's biography and realizing that businesses could do more than generate profit. They could tackle global problems such as disease, climate change, and human longevity. This shift led him into emerging fields like CRISPR gene editing, genomics, AI, robotics, and healthcare innovation. He explains the transformative potential of technologies that can edit DNA, improve quality of life, and help address diseases at their genetic roots.The conversation also explores the realities of building research-driven companies in a region traditionally known for trade rather than innovation. Mohamed discusses the importance of sovereign research and development, the future of cultured meat, the role of generic medicines in making healthcare more accessible, and why the Middle East must evolve from consuming technology to creating it. He shares insights on balancing long-term vision with financial sustainability and why entrepreneurs must embrace failure as part of the journey.At its core, this episode is about imagination. It is about questioning traditional paths, thinking beyond short-term gains, and having the courage to build solutions that can shape the future. Mohamed's story demonstrates how innovation begins when we dare to imagine possibilities that others cannot yet see.About The GuestMohamed Adel Fakhro is the Chairman of Infinite Loop, entrepreneur, investor, and technology advocate focused on advancing innovation across biotechnology, artificial intelligence, healthcare, and emerging technologies. Coming from one of Bahrain's most established merchant families, whose business heritage spans more than 138 years, he represents a new generation of leaders bridging traditional commerce with cutting-edge scientific progress.A graduate of Stanford University, Mohamed has spent his career exploring opportunities beyond conventional business sectors. His interests span genomics, gene editing, robotics, enterprise AI, pharmaceutical manufacturing, and healthcare accessibility. Through his ventures, he is actively working to develop technologies that improve human wellbeing while promoting regional self-sufficiency in critical sectors such as healthcare, food production, and advanced research.Passionate about long-term innovation, Mohamed advocates for stronger research and development ecosystems across the Middle East. His work reflects a belief that the region can become a creator of intellectual property and transformative technologies rather than simply a consumer of them. Through entrepreneurship, investment, and strategic leadership, he continues to champion ambitious ideas designed to address some of the world's most complex challenges.Quotes3:39 - Business can be about changing the world for the better. 22:00 - You have to believe in yourself and you have to just do it, basically. It's not about like I need to learn about how the cells develop and how the cells grow and why they grow and what temperature and all of that.  22:47 - My message to the younger generation would be to just imagine what they want, not necessarily to become the most knowledgeable person in the field, but just imagine how you could fix a problem and then just go for it.37:31 - As technology becomes more advanced, life becomes more slow. In fact, as it becomes more advanced, I think things will happen more and more quickly.Useful LinksWebsite:https://infiniteloop.bh/founder/Instagram:https://www.instagram.com/mofakhro1/LinkedIn :https://www.linkedin.com/in/mohamed-adel-fakhro/The Matrix Green Pill Podcast: https://thematrixgreenpill.com/ The Matrix Green Pill Podcast: https://thematrixgreenpill.com/Please review us: https://g.page/r/CS8IW35GvlraEAI/review

In this episode, Ray Cochrane unpacks how two colliding black holes revealed a whirlpool in spacetime, a direct detection of frame dragging hidden in the cleanest gravitational-wave signal ever recorded. Additional stories cover the James Webb Space Telescope, counting 16.5 million stars in the Cigar Galaxy, SpaceX rolling out Starship V3, deadly back-to-back earthquakes in Venezuela, GitHub fighting a California law that could break open source, and Meta engineering a battery narrow enough to live in a pair of glasses. – Want to start a podcast? It’s easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens with a personal update before the night’s lead story. He recently graduated with a Bachelor of Science in Computer Science from Portland State University, celebrated with family in town, and launched a new site at rayc.world. That site links to a final-project study he built on collaborative filtering using podcasting data, hosted at cohort.rayc.world and drawn from OP3 analytics. He also plans to return to the show’s classic twice-weekly cadence on Mondays and Thursdays. From there, he goes deep on a new black hole discovery, then pivots through space, earth science, climate, biotech, open source, cloud infrastructure, and consumer hardware. Colliding Black Holes Reveal a Whirlpool in Spacetime Two black holes spiraled together, merged, and sent a gravitational wave rippling across the universe. Researcher Neil Lu and colleagues at the Australian National University found the fingerprint of frame dragging buried in GW250114, the cleanest signal LIGO has ever recorded. Frame dragging means a spinning black hole drags spacetime around with it, like a spoon turning in honey, except the honey is reality itself. Remarkably, the wave changed the distance between your nose and your ear as it passed, by far less than the width of a single atom. Sponsor: GoDaddy Economy hosting is $6.99/month, WordPress hosting is $12.99/month, and domains are $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Webb Counts the Stars in the Cigar Galaxy NASA released a striking new James Webb Space Telescope view of Messier 82, the edge-on galaxy nicknamed the Cigar Galaxy. Because Webb sees in infrared, it peers straight through the dust that normally hides the galaxy’s interior. Combined with archival Hubble data, the image resolves roughly 16.5 million individual stars. M82 is a starburst galaxy, meaning it forms stars at a furious rate, a frenzy likely triggered when it merged with a neighbor. SpaceX Rolls Out Starship V3 SpaceX officially introduced Starship V3, the third generation of the largest rocket ever built. The vehicle now flies on the Raptor 3 engine, pushing liftoff thrust to around 20 million pounds and making it the most powerful rocket ever flown. More importantly, V3 is designed to carry over 100 metric tons to low Earth orbit while staying fully reusable, roughly triple the previous version. SpaceX also added in-orbit refueling hardware, the capability that finally makes operational Moon and Mars missions realistic. The Asteroid Barrage That Kept Earth From Forming Continents A team led by Curtin University and the Queensland University of Technology argues that relentless asteroid impacts shaped the very young Earth. During the Hadean, more than four billion years ago, the planet was struck far more often than it is today. Each impact dumped heat deep into the interior, repeatedly melting and reworking the crust. Consequently, stable continents formed much later than calmer models assumed, painting a picture of a hotter, weaker, more chaotic early Earth. Back-to-Back Earthquakes Devastate Northern Venezuela Northern Venezuela was struck by two major earthquakes on June 24, a magnitude 7.2 foreshock followed by a magnitude 7.5 mainshock. Both hit only about six miles underground, so the shallow shaking delivered its full force at the surface. Tragically, at least 164 people died, and the region sits along the tangled boundary where the Caribbean and South American plates grind past each other. These were the largest quakes to hit the area since a magnitude 7.7 event near Caracas in 1900. The ‘Guerrilla Solar’ Era Has Arrived A quiet energy shift, nicknamed “guerrilla solar,” is spreading across Europe. These small plug-in panels deliver power to a home’s wiring via a standard wall outlet, with no electrician or permit required. Germany now counts roughly a million of these systems. However, the U.S. payoff remains modest, with savings estimates of around $15 per month against a $500 to $1,500 setup cost. Why a Broken-Up Forest Stores Less Carbon Researchers quantified what foresters long suspected: an intact forest stores far more carbon than the same acreage split into fragments. A hectare inside a large, continuous forest proved about 38 percent more productive than an isolated one. The culprit is edge effects, the extra wind, heat, and direct sun that stress trees at a forest’s boundary. Because a large forest maintains a large protected core while fragments are nearly all edge, planting trees together matters for carbon storage. Edited Human Embryos Reveal a Surprise Researchers used base editing, a precise cousin of CRISPR that rewrites a single DNA letter without cutting the strand, in human embryos. They discovered that a protein called NANOG plays a role in early human development that it does not play in mice. In humans, switching it off still let cells form that seed the placenta and yolk sac. The finding argues that understanding human development requires studying human embryos directly, which reignites a thorny ethical debate. GitHub Fights a California Law That Could Break Open Source GitHub joined Black Forest Labs, Hugging Face, and Mozilla to push for fixes to California’s AI Transparency Act. As written, the bill could force revocation of an open-source license when a downstream user fails to meet certain obligations, which clashes with the permanent, irrevocable promise of open source. Cochrane pointed to curl and its longtime maintainer, Daniel Stenberg, warning that the rule could destabilize the supply chain on which the whole tech world runs. Instead, the coalition points to the EU’s AI Act transparency code as a saner model. Rust Opens Its Maintainers Fund The Rust Foundation launched a Maintainers Fund to pay the people who keep the language’s ecosystem healthy. Backed by RFC 3931, it establishes a funding team and a new Maintainer-in-Residence program for the often thankless work on the compiler, standard library, Cargo, and Clippy. Individuals can donate through GitHub Sponsors, while companies can sponsor there or contact the foundation directly. Cochrane urged any business that depends on open source to invest in the projects it actually uses. AWS Gives Lambda Its Own Isolated Sandboxes AWS introduced MicroVMs inside Lambda, its serverless platform. Each session runs in a dedicated micro virtual machine with no shared kernel and up to eight hours of total runtime. The feature exists for the AI era, in which applications increasingly run code written by an AI agent rather than by the developer. Use cases include AI coding assistants, data analytics platforms, vulnerability scanners, and game servers running user-supplied scripts. Meta Engineers a Battery Narrow Enough for Glasses Meta built custom steel-can battery cells as narrow as seven millimeters to fit the temple arms of smart glasses like the Ray-Ban Meta and Oakley Meta Vanguards. These cells power cameras, speakers, and AI features in a space most engineers would call impossible. To prevent brownouts, Meta swapped wound electrodes for precisely die-cut stacked layers that lower electrical resistance. Now the company is spreading the technology across multiple vendors and eyeing other wearables. Polestar Gets Locked Out of the US Market Starting in 2027, Polestar will not be able to sell its new models in the United States. A federal Connected Vehicle Rule bars cars containing certain Chinese or Russian software or hardware on national security grounds. The painful irony is that Polestar moved production of the Polestar 3 to South Carolina specifically to dodge tariffs on Chinese-built EVs. Because the rule targets the technology’s origin rather than its assembly location, the company is shut out anyway. Retroid’s Pocket Nova Packs Serious Power for $229 Retroid returned with a new retro handheld, the Pocket Nova, starting at $229 with a step-up model around $269. It features a 4.5-inch AMOLED screen in a 4:3 aspect ratio, a shape well suited to classic games. On paper, it should handle GameCube- and PlayStation 2-era titles, though that remains an early expectation rather than a benchmarked promise. Retroid has earned a strong reputation for high-quality, genuinely portable consoles. Cochrane signs off with the usual ecosystem mentions: GNC Insider at geeknewscentral.com/insider, the show newsletter, email at geeknews@gmail.com, and modern podcast app recommendations at podcastapps.com. The post Colliding Black Holes Reveal a Whirlpool in Spacetime #1866 appeared first on Geek News Central.

The applications to talk at SkeptiCamp in October are now open, don't be shy! In TWISH we hear about how the jesuit priest Angelo Secchi unwittingly became the origin of tales about green men on Mars. Then, it's time for the news:EUROPE / WORLD: European heatwave / El Niño officially under wayAUSTRIA: Study links authoritarian attitudes to belief in Anthroposophic medicineEUROPE / WORLD: Is EU falling for the great replacement theory?The European Commission gets today's award for being Really Right since they finally are easing the rules for CRISPR crops in the EU.In Who's Quacking? we feature Paulo Zampolli, sel-appointed “Envoy to Italy” who has tried to sneak Italy back into the World Cup, even though they clearly did not qualify.Enjoy!https://theesp.eu/podcast_archive/theesp-ep-537.htmlSegments:0:00:27 Intro0:00:51 Greetings0:03:25 TWISH0:10:38 News0:30:06 Really Right0:33:48 Who's Quacking?0:39:31 Quote0:40:57 Outro0:42:20 Outtakes Hosted on Acast. See acast.com/privacy for more information.

ASM Microbe is the largest microbiology meeting in the United States, bringing together thousands of scientists, laboratorians, clinicians, and industry partners to discuss the latest advances in microbiology. In this episode, Luis shares highlights from ASM Microbe 2026, including sessions on diagnostic challenges, antimicrobial resistance, rapid susceptibility testing, emerging therapeutics, laboratory automation, phage therapy, and whole-genome sequencing. Topics include a Brucella case that reinforces the importance of Gram stain interpretation, updates on resistance mechanisms in Pseudomonas aeruginosa and KPC-producing organisms, advances in rapid AST, and innovations showcased in the vendor hall. Luis also discusses several posters that caught his attention, covering pharyngeal gonorrhea, direct-from-specimen susceptibility testing, phage testing, rapid resistance reporting for Mycobacterium abscessus, and CRISPR-based diagnostics for bloodstream infections. Whether you attended ASM Microbe 2026 or couldn't make it this year, this episode provides a practical overview of some of the trends, technologies, and conversations shaping the future of clinical microbiology. Topics Discussed: • Diagnostic challenges in clinical microbiology • Rapid identification and susceptibility testing • Antimicrobial resistance and emerging therapies • ESKAPE pathogens and Pseudomonas aeruginosa • Laboratory automation and AI-assisted workflows • Phage therapy and phage susceptibility testing • Whole-genome sequencing and CRISPR diagnostics Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Some genetic variants may help explain why different psychiatric disorders share overlapping biology. In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Jess McAfee, PhD, and Alejandro Gomez from the University of North Carolina at Chapel Hill about their work studying pleiotropic variants associated with psychiatric disorders. Jess explains how genome-wide association studies can identify regions of the genome linked to disease risk, but often cannot pinpoint which specific variants are functionally important. Her work used massively parallel reporter assays, or MPRAs, to test whether different alleles in non-coding regulatory regions alter gene expression. Alejandro then describes how CRISPRi can help take the next step by targeting those variants in the genome and asking which nearby genes respond. Together, these approaches provide a clearer path from statistical genetic association to functional biological insight. The episode also highlights two early-career scientists whose paths into molecular biology were anything but linear. Jess moved from plant genetics to human genomics, while Alejandro shifted from chemistry and industry into CRISPR-based neuroscience research. Along the way, they reflect on mentorship, lab culture, persistence, AI, and the excitement of working with technologies that are still rapidly evolving. NOTE: This episode may contain general information relating to various medical conditions or their treatment.  This information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional.  Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

About this episode:   A group of students from suburban Atlanta has developed a new method for detecting Lyme disease using the gene-editing tool CRISPR. In this episode: why there's such a desperate need for a new diagnostic, how the students' model works, and why it's so promising for the treatment of Lyme and other diseases.  Guest:  Nicole Baumgarth, PhD, DVM, is Bloomberg Distinguished Professor in Molecular Microbiology and Immunology and the director of the Lyme and Tickborne Disease Research and Education Institute at the Johns Hopkins Bloomberg School of Public Health.  Sankalp Yeleti is a recent graduate of Lambert High School and a rising freshman at New York University, where he plans to study biomolecular science.  Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing—CBS News  Lancet—Lambert iGEM 2025 Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Welcome, Massimo Banzi of SuperModerno and co-founder of Arduino Introduction and SuperModerno: Massimo introduces himself as a “friendly nerd” and discusses his new project, SuperModerno The project aims to explain the “behind the scenes” of technology to prevent people from becoming “slaves to the platform” The History of Technology: Massimo expresses his passion for technology’s history, emphasizing non-American innovators to show Europeans they can also lead in technology, citing the UK-based origins of the Arm processor The Legacy of Olivetti: He highlights Olivetti (founded in 1908), which moved from typewriters to creating the Programma 101, the first desktop computer used by NASA to compute orbits for the Apollo program Design as a Differentiator: Olivetti was the first tech company to apply design to everything (products, posters, and architecture) This inspired Massimo's concept of the “invisible touch”, the idea that consistent, intentional design creates a unique connection with users and gives a company a competitive edge The Interaction Design Institute Ivrea (IDII): Massimo’s path led him to IDII, located in the former Olivetti research building, where he transitioned from a two-week sabbatical to a four-year stay Learning by Making: To help students with no electronics background, Massimo drew on how he learned as a seven-year-old (“learning by making”) to remove the friction of interacting with technology The Founding Team: He met Tom Igoe (ITP) and David Cuartielles, and they realized students were afraid to be creative because they feared “blowing up” expensive tools like the Basic Stamp The “Pizza and a Beer” Price Point: Massimo aimed for a hardware cost of 20 Euros, roughly what a student would spend on a pizza and a beer, to encourage experimentation Building the Platform: Along with David Mellis, the team adapted Processing (a language for artists) by “surgically” replacing Java with C++ to create the Arduino IDE Ivrea Manufacturing: Leveraging the industrial base of Ivrea and Torino (the “Detroit of Italy”), Massimo was able to find local PCB manufacturers and assemblers just a short drive away From Hacking to AVR: Massimo's early work involved hacking satellite TV PIC chips for soccer fans, but mentor Bill Verplank encouraged him to use AVR microcontrollers because they could be programmed simply in C Enabling Creators: Massimo shares stories of how Arduino enabled others, such as Josef Prusa, who started with Arduino as a teenager before building his global open-source 3D printer company The Innovation of Simplicity: Massimo argues that Arduino’s true innovation is the user experience This is measured by the “Time to First Blink”, the goal for a user to go from downloading software to blinking an LED in five minutes Standardization and “The Core”: Arduino became an ad-hoc standard by providing a compatibility layer across different microcontrollers Massimo believes in having a “small slice of a really large pie” by allowing other architectures to work within the ecosystem Hardware Architecture and the “Lasagna”: Inspired by the PC104 format, the board uses a layered approach where modules stack like a lasagna The “Shield of a King”: The name Arduino comes from King Arduino of Ivrea; David Cuartielles suggested that since the board was named after a king, the add-on modules should be called “Shields” Hardware Design Choices: The board fits a credit card size (to stay within the free version of Eagle software) and is blue because that color was thought to be less tiring for workers’ eyes Happy Accidents: The unique shape was chosen to be “ourselves instead of everyone else” During the design process, Massimo inadvertently moved a connector by half a step, creating an offset header that they kept for consistency after the first few thousand were made The Discovery of Auto-Reset: During a workshop in Germany, Massimo solved the frustration of manual resets by soldering a capacitor to the DTR pin, allowing the software to trigger the reset automatically The US Market and Legal Battles: Tom Igoe's adoption of Arduino at NYU helped the US become the project’s single biggest market This growth led to a difficult legal battle for control of the brand against a former partner Support from Arm: Massimo credits Arm Ltd (and CEO Simon Segars) for providing the strategic support that allowed the founders to regain control of the company. Massimo believes this is the first time he has talked about the role of Arm in the difficult legal process. Industrial and AI Expansion: Partnerships with Intel and Microsoft (Windows 10 IoT) led to early forays into TinyML (AI on small boards) back in 2017 The Qualcomm Acquisition: In October 2025, Qualcomm acquired Arduino, which Massimo sees as essential for bringing “advanced silicon” into the family to handle the increasing complexity of technology The “Arduino Formula” and Layering: Massimo views Arduino as a formula for simplification that can be applied to anything, including complex Linux machines like the Uno Q This is achieved by building in layers, where beginners use high-level abstractions and experts can “strip away” layers to reach the bare metal The Future Vision: Massimo looks forward to the “Arduino Formula” being applied to new fields, stating he is waiting for someone to develop an “Arduino for biology” using CRISPR and DNA technology

BUFFALO, NY – June 17, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 8, 2026, titled “DHHC3 interferes with antitumor immunity in melanoma cells.” The study was led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler from the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. Melanoma is one of the most aggressive forms of skin cancer and is highly influenced by interactions between tumor cells and the immune system. Although modern immunotherapies have transformed treatment for many patients, researchers continue to search for molecular mechanisms that enable tumors to evade immune attack and continue growing. In this study, researchers investigated DHHC3, a protein acyltransferase that regulates protein palmitoylation and helps maintain cellular redox balance. Previous studies had linked elevated DHHC3 expression to poor outcomes in several cancers, but its role in melanoma and anti-tumor immunity remained unclear. To explore this question, the team used CRISPR gene editing to eliminate DHHC3 expression in B16F10 melanoma cells. Loss of DHHC3 caused a marked increase in oxidative stress and cellular senescence, as demonstrated by elevated TXNIP expression, increased reactive oxygen species levels, and enhanced expression of senescence-associated markers. Full press release - https://www.oncotarget.net/2026/06/17/protein-linked-to-melanoma-growth-may-suppress-the-bodys-natural-anti-tumor-immune-response/ DOI - https://doi.org/10.18632/oncotarget.28880 Correspondence to - Martin E. Hemler - martin_hemler@dfci.harvard.edu, and Chandan Sharma - csharma@mgh.harvard.edu Abstract video - https://www.youtube.com/watch?v=QQhP2VhzKSE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28880 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Thomas is joined by Dr. Eric Jaffe, biologist, dinosaur enthusiast, and high school biology teacher, for a conversation that starts with a deceptively simple question: what are biological definitions actually doing? It turns out that biology is far more like history than math, and that difference has enormous consequences for anyone trying to weaponize phrases like "the biological definition of sex." Dr. Jaffe walks through why definitions in inductive sciences are descriptive, not prescriptive, and what that means for species, chromosomes, fungi, LeBron James, and trans people. "Exceptions aren't the exceptions in biology. They are built into what we call biological systems." Plus: Patreon Q&A questions on alien DNA, how new chromosomes evolve, the 97% chimp figure, CRISPR vs. what came before, and Trump's research budget cuts. Cells at Work (anime recommended by Dr. Jaffe) Project Hail Mary (film referenced) Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailIf you enjoyed this deep dive on cloning and genetic modification, hit subscribe, drop a comment with your take — should we bring back the woolly mammoth? — and share the episode with the friend who still thinks Walt Disney's head is in a freezer.Cloning and genetic modification get blended together constantly in pop culture, so this episode breaks down what's actually real, what's a myth, and how we got from a frog tadpole in 1952 to dire wolf pups in 2025.Brian, Thomas, and producer Corey (it's Corey's birthday) walk through the full history and science of cloning — admitting up front they're not scientists, just three guys following a rabbit hole that started with a family cloning their dog, CRISPR edits, and the Lone Star tick. From there it turns into a surprisingly thorough tour of how copying and editing life actually works.The episode untangles the four ideas people constantly confuse: cloning (a genetic copy, same DNA), genetic modification / gene editing (changing genes, like CRISPR), de-extinction (reviving a lost species), and chimeras (mixing cells from two species). With that foundation set, the crew traces the timeline from Yves Delage's 1895 nuclear transplantation concept and Hans Spemann's 1938 "fantastical experiment," through the first nuclear transfer in 1952, John Gurdon's Nobel Prize work, and Dolly the sheep — the first mammal cloned from an adult cell, born July 5, 1996.If you've ever wondered whether you can really clone your pet, this one answers it: it's real, it's commercial, and it's expensive. They cover the actual companies and price tags, why a clone is not a resurrection, and why the Humane Society pushes back on the practice. The conversation also gets into man-animal hybrids — the bizarre real story of Soviet scientist Ilya Ivanov — and busts the myth that Stalin wanted an army of ape-man super soldiers.This is for anyone curious about CRISPR, stem cell medicine, de-extinction headlines, and the ethics underneath all of it: human-animal chimeras grown for transplant organs, the 100,000+ Americans on the organ waiting list, and whether reproductive human cloning should stay banned. Expect the science (telomeres, Large Offspring Syndrome, the brutal 1–5% survival rate) alongside the kind of unfiltered, off-the-rails commentary the show is known for.By the end you'll understand why the 2025 "dire wolf" isn't really a dire wolf, what the Bucardo's grim record actually was, and why mules — and ligers — can't be bred the way you'd think. It's a fast, funny, fact-checked crash course in one of the wildest fields in modern science.New episodes of The Days Grimm Podcast drop regularly — history, science, true crime, and whatever rabbit hole Tom drags everyone into next.TIMELINE:00:00 — Cold open & welcome (Corey's birthday)01:58 — Today's deep dive: cloning and genetic modification02:07 — "We're not scientists" disclaimer03:04 — Why Tom picked this: CRISPR, the Lone Star tick & a cloned dog04:34 — 1895: the first nuclear transplantation concept06:21 — The 4 things people confuse: cloning, gene editing, de-extinction & chimeras07:07 — Why the 2025 "dire wolf" is really edited gray wolf11:16 — 1952 leopard frogs & John Gurdon's Nobel work12:30 — Dolly the sheep and why she mattered14:00 — Why mules (and ligers) can't reproduce16:46 — How cloning actually works (somatic cell nuclear transfer)20:26 — What we've cloned so far + first primate clones (2018)21:54 — Can you clone your pet? The real companies and prices23:51 — A clone is not a resurrection + welfare concerns25:01 — Man-animal hybrids & the Soviet Ivanov story27:00 — Chimeras for medicine and pig organ transplants32:00 — De-extinction & the Bucardo: "extinct twice"33:47 — The black-footed ferret success story34:30 — 2025 dire wolf pups & the woolly mouse37:00 — Telomeres, Large Offspring Syndrome & failure rates39:30 — Ethics: mammoths, pets, chimeras & human cloning41:00 — Busting the Walt Disney frozen-head myth42:30 — Wrap-up[The Days Grimm Podcast Links]- YouTube: https://www.youtube.com/c/TheDaysGrimm- Our link tree: linktr.ee/Thedaysgrimm- GoFundMe account for The Days Grimm: https://gofund.me/02527e7c [The Days Grimm is brought to you by]Sadness & ADHD (non-medicated)

More than just a game—Knicks overcoming odds in game 4 comeback is a parable of resilience; A one and done lifetime cholesterol fix via gene modification; Will cataract surgery interfere with benefits of light exposure? Do amounts of vitamin A in various supplements taken together court the risk of toxicity? Smartphones and social media create real harm for adolescents; Experts determine the exact right amount of sleep down to the minute—but is it overreach? 

Episode 377 Considered too dangerous and unreliable a few years ago, the technology for gene editing babies is advancing fast. Improved methods of using CRISPR gene editing are making the technique safer and more targeted. But does that mean we should be creating designer babies? A new, more powerful version of CRISPR has already saved lives by correcting cells in children linked to leukaemia. But editing human embryos is a different story - and less safe. Despite this, researchers have been studying whether it's possible. To discuss the obstacles that still need to be overcome and the ethical challenges, Rowan Hooper is joined by reporter Michael Le Page.To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a recap of the top 10 posts on Hacker News on June 12, 2026. This podcast was generated by wondercraft.ai (00:30): Statement on US government directive to suspend access to Fable 5 and Mythos 5Original post: https://news.ycombinator.com/item?id=48511072&utm_source=wondercraft_ai(01:58): AI agent bankrupted their operator while trying to scan DN42Original post: https://news.ycombinator.com/item?id=48500012&utm_source=wondercraft_ai(03:26): CRISPR tech selectively shreds cancer cells, including "undruggable" cancersOriginal post: https://news.ycombinator.com/item?id=48505231&utm_source=wondercraft_ai(04:55): Claude Fable is relentlessly proactiveOriginal post: https://news.ycombinator.com/item?id=48498573&utm_source=wondercraft_ai(06:23): Nobody ever gets credit for fixing problems that never happened (2001) [pdf]Original post: https://news.ycombinator.com/item?id=48498385&utm_source=wondercraft_ai(07:52): Open source AI must winOriginal post: https://news.ycombinator.com/item?id=48511908&utm_source=wondercraft_ai(09:20): Kimi K2.7-Code: open-source coding model with better token efficiencyOriginal post: https://news.ycombinator.com/item?id=48502347&utm_source=wondercraft_ai(10:49): "Don't You Just Upload It to ChatGPT?"Original post: https://news.ycombinator.com/item?id=48507278&utm_source=wondercraft_ai(12:17): Electric motors with no rare earthsOriginal post: https://news.ycombinator.com/item?id=48510010&utm_source=wondercraft_ai(13:46): How to setup a local coding agent on macOSOriginal post: https://news.ycombinator.com/item?id=48507020&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

The career path -- M.S. in Neuroscience to filmmaking -- is a wholly original one and so is his filmmaking. His second feature, PONDEROSA (2026), is a comedy-horror film that looks at American masculinity in a way I've never seen before. It is a gift to watch -- beginning to end -- not because I understood everything going on, but because I didn't.The best type of filmmaking should challenge you and make you think differently about the world around you. Mission accomplished here by Rob, with brilliant actors by his side. I'm texting my friend with a neuroscience degree, telling him to get on over to Tribeca and make a film!In this episode, Rob and I talk about:going from CRISPR engineer to filmmaking;how PONDEROSA came about and the trickiness of describing the film;what his experiences at prominent film festivals taught him;how he got some of the best actors out there -- Bill Camp; Alexis Bledel -- to work on his film;how he did the score and music FIRST and then edited accordingly;how he balances directing and producing;what's next for him.Rob's Indie Film Highlight: THE MISCONCEIVED (2026) dir. by James N. Kienitz WilkinsLinks:Follow Rob On Instagram

Send us Fan MailSomebody left the heat on in the Midwest, and we're feeling every degree of it. We start with the kind of summer heat wave that messes with your sleep, forces the air conditioner decision, and makes you stare at the electric bill like it's a personal betrayal. Then we lighten it up with a “supposedly accurate” weather tour that lets you compare your day to places like Beijing, Moscow, the Australian Plains, Phoenix, Spokane, Tokyo, and our own backyard in Southern Illinois complete with humidity, UV index, wind, visibility, and air quality.The mood turns when we talk about severe storms and outages up north, and we share a quick note for soccer fans about the upcoming FIFA World Cup 2026 schedule and the unique North America hosting setup. After that, we shift into an earthquake report with weekly totals and the sobering reality of major quakes, including a 7.8 earthquake near the Philippines, the tsunami warning, and what it's like to watch aftershocks stack up when people are already shaken and vulnerable. One of the hardest parts is admitting it out loud: earthquake warnings still aren't where they need to be, and that gap costs real people real safety.We close with the question that ties a surprising list of sci-fi movies together from Gattaca to Wrath Of Khan: genetic modification. CRISPR gene editing isn't just a plot device anymore, and headlines about embryo genome editing raise the same moral dilemma those stories keep shouting at us: just because we can, should we. If you care about heat waves, disaster news, earthquake preparedness, bioethics, and where genetic engineering might lead, you'll find plenty to wrestle with here.Subscribe, share the show with a friend, and leave a review if our mix of curiosity, faith, and oddball reporting gives you something to think about.Support the show I hope you enjoy the show!  If you find value in our show,Pray for us! Send Us Positive vibes.Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow.Contact Us. Email: theuglyquackingduck@gmail.com. Send Us Fan Mail: Under our description on any podcast player you will find a link you can text us or record a message. Leave a voice message: Just letting us know you are out there listening is a big boost!Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costsAnyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce  Email:          theuglyquackingduck@gmail.comWebsite:     https://theuglyquackingduck.com/

Send us Fan MailSomebody left the heat on in the Midwest, and we're feeling every degree of it. We start with the kind of summer heat wave that messes with your sleep, forces the air conditioner decision, and makes you stare at the electric bill like it's a personal betrayal. Then we lighten it up with a “supposedly accurate” weather tour that lets you compare your day to places like Beijing, Moscow, the Australian Plains, Phoenix, Spokane, Tokyo, and our own backyard in Southern Illinois complete with humidity, UV index, wind, visibility, and air quality.The mood turns when we talk about severe storms and outages up north, and we share a quick note for soccer fans about the upcoming FIFA World Cup 2026 schedule and the unique North America hosting setup. After that, we shift into an earthquake report with weekly totals and the sobering reality of major quakes, including a 7.8 earthquake near the Philippines, the tsunami warning, and what it's like to watch aftershocks stack up when people are already shaken and vulnerable. One of the hardest parts is admitting it out loud: earthquake warnings still aren't where they need to be, and that gap costs real people real safety.We close with the question that ties a surprising list of sci-fi movies together from Gattaca to Wrath Of Khan: genetic modification. CRISPR gene editing isn't just a plot device anymore, and headlines about embryo genome editing raise the same moral dilemma those stories keep shouting at us: just because we can, should we. If you care about heat waves, disaster news, earthquake preparedness, bioethics, and where genetic engineering might lead, you'll find plenty to wrestle with here.Subscribe, share the show with a friend, and leave a review if our mix of curiosity, faith, and oddball reporting gives you something to think about.Support the show I hope you enjoy the show!  If you find value in our show,Pray for us! Send Us Positive vibes.Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow.Contact Us. Email: theuglyquackingduck@gmail.com. Send Us Fan Mail: Under our description on any podcast player you will find a link you can text us or record a message. Leave a voice message: Just letting us know you are out there listening is a big boost!Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costsAnyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce  Email:          theuglyquackingduck@gmail.comWebsite:     https://theuglyquackingduck.com/

One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.

In this episode of Moving Medicine Forward, Dr. Robert Fisher—one of the pioneers of modern transplant surgery—explores the rapidly advancing field of xenotransplantation and why it may represent a true turning point in medicine.From CRISPR-driven genetic engineering to breakthroughs in immunosuppression and scalable organ production, Dr. Fisher breaks down how decades of research are converging to make cross-species organ transplants a clinical reality.The conversation also dives into what this means for patients, how it could transform transplant access, and the critical role of rigorous, collaborative clinical research in translating breakthrough science into real-world care.01:23 Dr. Fisher's path into transplant surgery03:05 Why xenotransplantation is reaching a turning point (CRISPR + immunosuppression)04:47 Advances enabling scalability, safety, and compatibility 08:32 Ethics, risks, and clearing misconceptions10:27 Real-world patient impact and clinical considerations 13:10 Logistics, coordination, and clinical execution15:49 New immunosuppression strategies driving success17:44 Collaboration, ethics, and managing risk 20:49 Eliminating waitlists: expanding access to transplant22:54 Milestones toward adoption and future outlook

We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Most of biotech runs on a tiny handful of "model" organisms — E. coli, baker's yeast — while millions of wild species sit unstudied in what scientists call microbial dark matter. In this episode, Karl and Erum sit down with Henry Lee, co-founder of Cultivarium, to explore why the future of synthetic biology depends on learning to grow, study, and engineer the organisms we've ignored. Henry breaks down the real difference between model and non-model organisms, why simply culturing a new microbe can take years, and how Cultivarium is standardizing growth recipes and building an open digital platform so any researcher can work with strains that were once impossible to handle. Along the way: a fistulated cow, a spectacular failure that ultimately cracked the genetics of cement-making bacteria, extreme microbes that could free fermentation from fresh water, and Cultivarium's evolution from a Focused Research Organization into a "Frontier Research Contractor." The conversation closes on the state of American science — funding, public trust, and AI — plus the America's Living Library Act and a quick-fire round on archaea, overused buzzwords, and whether we're alone in the universe. Before the interview, Karl and Erum spill some biotech tea on "Biotech Barbie" Cathy Tie and unpack what the video game Stray gets right about engineered microbes escaping into the wild.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) — Summer vibes & a little biotech gossip: meet "Biotech Barbie"(00:07:42) — What a video game about a lost cat teaches us about runaway microbes(00:12:38) — How Henry went from building circuits to falling for biology(00:16:25) — So what actually is a "non-model" organism?(00:22:30) — Yes, we really talk about a cow with a window in its stomach(00:25:40) — Step inside Cultivarium: incubators, recipes & happy accidents(00:33:35) — Borrowing nature's best ideas: fungi, archaea & glowing jellyfish(00:39:15) — The failure that taught us everything (a cement-making bacteria story)(00:43:45) — Could the ocean fuel the future of fermentation?(00:48:45) — Real talk: science funding, public trust & the promise of AI(00:53:25) — Reinventing how big science gets funded — and a library of life(01:00:10) — Dream organisms, pet-peeve buzzwords & "are we alone?"(01:05:55) — Karl & Erum unpack their favorite momentsLinks and Resources:CultivariumBiosphere Project27. Charting the Unexplored Microverse for Biological Gold with CULTIVARIUM's Nili Ostrov147. Shhh…They're Talking: Holoclara's Dr. Andrea Choe Tunes Into Worm Signals for Health98. Gotta Get Them All: bitBiome's Quest to Decode All Microbes with Yuji Suzuki183. The American Biotech Blueprint: Senator Todd Young on Biodiversity as National SecurityKathy Tie Biotech Barbie Gene EditingStray - A Synthetic Biology Video GameBioInnovations Events - For 25% off use code: Grow EverythingTopics Covered:non-model organisms, microbial dark matter, model organisms, Cultivarium, industrial biotechnology, microbial engineering, DNA repair, CRISPR, fermentation, frontier research contractorHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Un grupo de científicos de la Universidad de Georgia quería entender mejor la vasopresina, una hormona clave en la cooperación, la amistad y el autocontrol. Para ello, desactivaron sus receptores en un grupo de hámsters usando la tecnología CRISPR. Esperaban roedores más pacíficos y gregarios. Obtuvieron justo lo contrario: pequeñas alimañas violentas dispuestas a despedazar a cualquier congénere. El resultado abre una pregunta incómoda: ¿y si la agresividad fuese el comportamiento por defecto de los mamíferos, y solo una hormona nos separa del caos? Hablamos de bioquímica, de futuras terapias para individuos violentos… y de aplicaciones militares que dan bastante más miedo que cualquier película de terror. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

What is the future of gene editing with CRISPR? Has AI changed mathematics forever? Will we find other civilizations in the universe? What if we've been wrong about dark energy all along? These are just a few of the big, bold questions we'll be exploring in the new season of The Joy of Why. Mathematician Steven Strogatz and physicist Janna Levin are back as your hosts for these and other conversations that explore the frontiers of basic science and mathematics. Each episode features an in-depth conversation in which Steven or Janna sits down with a leading scientist or mathematician to unpack one big idea or area of research. The two hosts also chat together throughout each episode, sharing their own thoughts, reactions, and questions.

Our guests today are Ryan Jackson and Ned Weinshenker. We discuss a new CRISPR system that can be used to selectively kill cells, and some recent breakthroughs in the growing technology.

We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap

We are hearing a lot about gene Therapy and CRISPR technology. Mark's guest shared some wonderful healing examples and where we are going with this amazing science. Hear this from Dr. Lindsay George from CHOP about the exciting new health world ahead of us all on The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

In today's episode, I break down DNA, where it is found, and what it represents from a scientific and biblical standpoint. I discuss CRISPR, the genome, gene drives, and methylation. Is this innocent innovation or planned biological control and rewriting? #DNA #blood #Biblical #creation #CRISPR #genedrives #consent #coersion #control #accountability #GOD

Most receptors come with a history. Remulate came with a name — and almost nothing else. Dr. Beatriz Redondo, group leader at the University of Leipzig, has spent the last nine years building the first systematic characterization of adhesion GPCRs in Drosophila, including three receptors so new they were named after condiments. What she's constructing isn't just a receptor profile — it's a method for doing discovery when the tools don't exist yet.Dr. Redondo uses CRISPR, genetic tagging, and in vivo behavioral assays to place and characterize adhesion GPCRs in a system where generations turn over in weeks. Her work on remulate — a neuronal adhesion GPCR with a human ortholog linked to vascular malformations and blood-brain barrier dysfunction — is among the first of its kind in any organism.Key takeaways:Why Drosophila remains a productive system for receptor discovery in the genomics eraHow CRISPR and epitope tagging replace antibody-based tools for understudied GPCRsWhat nocifensive behavior in larvae reveals about remulate's neuronal functionHow basic science in an insect model connects to vertebrate disease biologyWhat it looks like to characterize a receptor from scratch — with no prior literature to build onDr. GPCR University — live and on-demand courses for scientists working on real discovery problems: https://www.ecosystem.drgpcr.com/gpcr-universityThis episode is supported by Eurofins DiscoverX and GeneTex: https://www.ecosystem.drgpcr.com/eurofins-discoverx | https://www.ecosystem.drgpcr.com/genetex

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Este episodio especial está diseñado para sorprender a los oyentes con hechos reales sobre el futuro de la salud humana, alejándose de los fenómenos inexplicables tradicionales del programa para centrarse en los asombrosos avances de la ciencia médica actual. El guion explora cómo la convergencia de los datos masivos, la inteligencia artificial y la biología molecular ha acelerado la innovación de manera sin precedentes. A lo largo del programa, se detallan hitos revolucionarios que ya son una realidad, como las terapias génicas hiperpersonalizadas con CRISPR, el uso de la tecnología de ARN mensajero para combatir tumores específicos y los xenotrasplantes con órganos de cerdos modificados genéticamente. Además, se aborda la detección precoz del cáncer mediante biopsias líquidas, los enfoques científicos para la longevidad y los esfuerzos de la medicina regenerativa para construir nuevos tejidos desde cero. Sin embargo, el episodio mantiene una postura crítica y honesta al discutir también las sombras de esta revolución, cuestionando el alto costo de los tratamientos, la desigualdad en la investigación global y los profundos dilemas éticos que surgen al intervenir en la naturaleza humana. #LaRuedaDelMisterio #FuturoDeLaMedicina #CienciaYSalud #Biotecnología #MedicinaPersonalizada #CRISPR #Bioética laruedadelmisterio2010@gmail.com ®© La Rueda del MisterioEscucha este episodio completo y accede a todo el contenido exclusivo de La Rueda del Misterio. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/4754

Check out BeerBiceps SkillHouse Courses Here - https://www.bbskillhouse.comFor all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsCheck out my Mind Performance app: Level SuperMindLink:- https://level4665.u9ilnk.me/d/F1ZOZV4OnTShare your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Join the Level Community Here:https://linktr.ee/levelsupermindcommunityFollow BeerBiceps SkillHouse's Social Media Handles:YouTube: https://www.youtube.com/@BeerBicepsSkillHouseInstagram: https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comFollow Dr. Niraj Rai's Social Media Handles:-Instagram: https://www.instagram.com/nirajbiotechgju X: https://www.instagram.com/nirajbiotechgjuIn this special episode 506th of The Ranveer Show, we are joined by Dr. Niraj Rai, a leading scientist in genetics, who shares deep insights on DNA, Human Evolution, Indian Ancestry, and Health. This episode takes you into the mysteries of our genetic code, the history of Indian populations, and how our environment shapes our biology.In this conversation with Dr. Niraj Rai, we talk about the 98% Mystery DNA, the impact of inbreeding in Indian communities, the "Heart Attack Gene" specific to South Asia, and the future of CRISPR technology. We also understand how genetics can reveal our true history, from the Indus Valley Civilization to the migrations that shaped modern India.This episode also covers the Gut Microbiome, the science behind the Gotra system, the evolutionary role of proteins, and how stress and happiness affect our genetic expression. We explore the differences between ancient and modern humans and the possibility of superhuman traits hidden within us.(00:00) – Start of the episode(01:59) – Dr. Niraj Rai Returns to TRS(02:55) – The Infinite Mystery of Human DNA(05:15) – Secret of the "Warrior Clan" Proteins(08:27) – Are we 99.9% the same?(11:49) – Why Chimpanzees are 6x Stronger than Humans(14:08) – AI & the Future of Genetic Engineering(16:52) – Epigenetics: How Mood changes your Biology(19:39) – Is the Indian Genetic Code deteriorating?(21:47) – Biohacking with Stem Cells & CRISPR(25:46) – The Harsh Truth about Caste-based Inbreeding(28:30) – Why Indians are prone to Heart Attacks(32:33) – Natural Selection & Virus Outbreaks(35:52) – What did Ancient Indians really eat?(42:54) – Is Autism the next stage of Human Evolution?(47:27) – Why Humans are losing Physical Strength(51:13) – The Genetic selection for Fair Skin in India(55:26) – CRISPR: Technology to create Super-Humans(1:07:27) – Why Punjabis have "Milk-Digesting" Genes(1:11:28) – Ancient Invasions & Genetic Mixing(1:18:33) – Scientific Logic behind the Gotra System(1:22:32) – Roman & Persian DNA in South India(1:26:14) – Criminal Genes & Inherited Trauma(1:28:37) – Hypoxia Therapy for Depression(1:34:25) – End of the episode

Ginny Yurich sits down with Dr. Sina McCullough for one of the most eye-opening conversations we've had on The 1000 Hours Outside Podcast. Sina shares how a devastating health collapse led her from a PhD in nutrition to questioning everything she thought she knew about the American food system. Together they unpack why ultra-processed food is so cheap, how the farm bill reshaped the modern grocery store, and what's really happening with gene-edited foods, pharmaceutical crops, CRISPR technology, and the hidden chemicals most families never even realize they're consuming. But this episode is not rooted in fear. It's about remembering that our daily choices still matter, that real food can help the body heal, and that ordinary people have more power than they've been led to believe. This conversation will make you look at your pantry, your plate, and your family's future differently. Sign up for the Two Days of Truth here Check out Dr. Sina McCullough's new book: Hands Off My FoodCheck out the Beyond Labels podcast Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailSubscribe and unleash your inner science goblin. We see you. We respect it.What happens when your DNA makes a typo?In this episode of Wildly Curious, Katy Reiss and Laura Fawks Lapole dive into the strange, fascinating world of genetic mutations—the tiny changes in DNA that can shape evolution, alter proteins, create disease, or sometimes do absolutely nothing at all. From harmless genetic quirks to serious inherited disorders, this episode breaks down some of the most important mutation types in a way that actually makes sense.

In this episode of the AgCulture Podcast, Paul sits down with Bob Miller, founder of Miller Hybrids, to unpack what it really takes to build a seed company in an industry dominated by global giants. From his early days in plant breeding to launching his own company in the middle of industry consolidation, Bob shares a perspective that challenges much of how modern seed is developed, tested, and sold.This conversation dives deep into why most seed is bred for “perfect conditions” instead of real farms, how Miller Hybrids tests genetics differently to create more stable performance, and why conventional corn is quietly making a comeback. Bob also breaks down the economics behind traits, the real role of GMOs, and where farmers may be overpaying for protection they don't actually need.If you've ever wondered whether bigger companies actually mean better seed—or what the future of genetics, CRISPR, and farm profitability really looks like—this episode will make you think differently about every seed decision you make.MEET THE GUESTBob Miller is a respected corn breeder and the founder and owner of Miller Hybrids, a family-owned seed company based in Kalona, Iowa.Born on a dairy and crop farm in northwest Ohio, Miller developed an early fascination with corn hybrids and their ability to handle stress and maximize yields. He built a distinguished career as a corn breeder with major seed companies, including Syngenta,where he developed successful commercial inbred lines and hybrids. His work emphasized improved emergence, yield stability, and drought tolerance.In 2005, he founded Miller Hybrids (originally B.O.B. Seeds, standing for "Best of the Best") to create a more hands-on, farmer-focused operation. As owner, president, and research director, Miller leads the company's breeding and testing programs. He develops corn hybrids tailored for the average farm, rigorously testing them across diverse soil types, stress conditions, and real-world environments like corn-on-corn rotations.Miller is deeply committed to empowering farmers. He believes in building reliable products that raise farm averages rather than chasing only top-end yields in ideal conditions. His family company (with his wife Pam) emphasizes personal attention, direct access to the breeder, and genetics that deliver stable, high performance for everyday growers.Through Miller Hybrids, Bob continues his lifelong passion for practical plant breeding, blending decades of industry expertise with the independence of a family business to support American agriculture.To learn more about Miller Hybrids, check out their website: https://www.millerhybrids.com/

Joined by Heidi Luv (Unfiltered Rise) to discuss blood doping, golden blood, Rh factor, and CRISPR technology. We delve into types of blood doping, military involvement, super soldiers, DARPA, and much more! Follow Heidi at https://open.spotify.com/show/4pzqktZNcGNZhzAeF9Zd3Q?si=BLmOZCUrTfe2o5XuGqYW7g www.unfilteredrisepodcast.com IG @unfilteredrise_podcast   X @UnfilteredRise On Patreon  #blooddoping #goldenblood #CRISPR #DNA #military #DARPA #supersoldiers #EPO #Autologous #syntheticoxygencarriers #bloodclots #damage #diseases #ATP #Rh #internationalregistry #blood #bloodcard #bloodlines #aliens #Nephilim

In part two of this two part episode, Jack continues their look into the dubious practice of “de-extinction” this time as it is pushed in the 21st century by Colossal BioSciences. Created in 2019 by Ben Lamm and George Church, Colossal aims at making extinction, as well as the endangered species list, a thing of the past using CRISPR technology. Claiming to have revived the Dire Wolf and Red Wolf, the company actually has been more successful in massive PR campaigns and paying off critics than reversing species death. But who benefits when people believe that the ecosystem can be preserved through test tubes rather than policy aimed at protecting endangered animals? You guessed it: wealthy sociopaths who see traditional conservation efforts as a barrier to total planetary domination. Gimmie Truth by Brad Abrahams https://bradabrahams.net/independent/gimme-truth-be7s6 Subscribe for $5 a month to get all the premium episodes: www.patreon.com/qaa Check out our new podcast series network Cursed Media! Spectral Voyager Season 2 is releasing now! Binge the entirety of Truly Tradly Deeply by Annie Kelly and Megan Kelly as well as Science in Transition by Liv Agar and Spencer Barrows: cursedmedia.net Produced by Liv Agar & Corey Klotz. Theme by Nick Sena. Additional music by Pontus Berghe. Theme Vocals by THEY/LIVE (instagram.com/theyylivve / sptfy.com/QrDm). Cover Art by Pedro Correa: (pedrocorrea.com) qaapodcast.com QAA was known as the QAnon Anonymous podcast.

Weichert details the downfall of Charles Lieber, a Harvard scientist and DARPA researcher recruited by the Thousand Talents Program to mirror his nanotechnology work in Wuhan, later convicted for making false statements and hiding Chinese bank accounts. The discussion shifts to CRISPR technology and He Jiankui's controversial genetic splicing on human twins, which reportedly resulted in unintended brain augmentations. Weichert warns that China views biotechnology as "dual-use," meaning advancements intended for civilian health are simultaneously being weaponized by the People's Liberation Army. (2)1937 SHANGHAI IMPERIAL JAPANESE NAVY FLAGSHIP

If a species is horrible enough, do we have the right to kill it forever? Seventy years ago, a nightmare parasite feasted on the live flesh of warm-blooded creatures in North America: the screwworm. That is, until a young scientist named Edward F. Knipling discovered a crucial screwworm weakness and hatched a sweeping project to wipe them out. Knipling's seemingly zany plan to spray screwworms out of planes all over the continent— with US taxpayer money— succeeded, becoming one of humanity's biggest environmental interventions ever.  Today, screwworms have been gone so long that none of us in North America even remember them. But now, they're coming back. And they're forcing us to ask: in an era of climate change and rapid mass extinction— should we kill off a species on purpose?  Special thanks to James P. Collins, Max Scott, Amy Murillo, Daniel Griffin, Phil Kaufman, Katie Barnhill, Arthur Caplan, Ron Sandler, Yasha Rohwer, Aaron Keefe, Gwendolyn Bogard, Maria Sabate, Meredith Asbury, and Joanne Padrón CarneyEPISODE CREDITS:  Reported by - Sarah Qari with help from - Latif Nasser Produced by - Sarah Qari Sound design contributed by - Sarah Qari Fact-checking by - Emily Krieger EPISODE CITATIONS: **The latest information on screwworm outbreaks and precautions: screwworm.gov Videos: Oral history interviews of Edward F. Knipling: here (https://zpr.io/njhMedFN5jsZ) and here (https://zpr.io/VQReQbfznCrq)  Podcasts: Here's a Spotify playlist (https://zpr.io/PNMEM274G7vh)  of all of our Golden Goose-inspired episodes! Sam Kean's podcast The Disappearing Spoon – his episode about screwworms is called The Screwiest and Perhaps Most Original Idea of the 20th Century (https://zpr.io/UYf6dR2yG3eN)  Our episode on CRISPR & gene drives (https://zpr.io/UYf6dR2yG3eN)  New to Radiolab? Check out our Radiolab Starter Kit (https://zpr.io/QpPnrHAZVQLR)  playlist of all-time favorite episodes! Articles: Sarah Zhang's latest piece in The Atlantic: American Milk Has Changed (https://zpr.io/xebbdq2MWV4L)  Her most recent piece on screwworms: The ‘Man-Eater' Screwworm Is Coming (https://zpr.io/ECmjCs7ScbS4)  Her initial reporting on screwworms: America's Never-Ending Battle Against Flesh-Eating Worms (https://zpr.io/PNMEM274G7vh)  Gregory Kaebnick's paper (https://zpr.io/yqNC3q5FbCcq)  about screwworm eradication in Science Archival materials:  The USDA's Screwworm Eradication Records (https://zpr.io/dY7zuVdGYKjf) contain lots of cool images and letters Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.